Sequence LifeScience
Open enrollment with a later-stage pipeline tilt
According to ClinicalTrials.gov-derived indexes, Sequence LifeScience sits in the upper half of US sponsors by registered trial count (#4,885 of 15,742 sponsors by registered trial count).
Sequence LifeScience: 2 sponsored US clinical trials, 2 recruiting.
Sequence LifeScience sponsors 2 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting. 2 of these trials are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Ulcer Foot, with 1 trials.
Mid-pack sponsor footprint
Sequence LifeScience is in the upper half of sponsors by trial count (#4,885 of 15,742 sponsors by registered trial count). Use the pipeline list and therapeutic areas to see what drives that mid-pack volume.
Open and recent trials
2 total, page 1 of 1
Study Title: A Multicenter, Prospective, Modified Platform Trial Evaluating Several Cellular, Acellular, and Matrix-like Products (CAMPs) and Standard of Care Versus Matched Standard of Care Controls in the Management of Nonhealing Pressure Ulcers.
NCT07665268
Randomized Evaluation of Nonhealing Diabetic Foot Ulcers With Exclusive Wound Therapy
NCT07086443
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 4 | 2 |
Therapeutic Areas
Where Sequence LifeScience enrollment is open (later-stage tilt)
2 recruiting of 2 indexed (100% open).
Phase mix: 2 late (III/IV) vs 0 early (I/II) (later-stage heavy).
Top condition: Ulcer Foot (1 trial), 6 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Sequence LifeScience: open-pipeline peers nationwide
Peers matched on 2 registered trials and 100% open enrollment, not the therapeutic-area sidebar.
Sequence LifeScience sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 2 trials (± recruiting share)
- 1200 Pharma · 2 trials · 50% recruiting
- 1ST Biotherapeutics · 2 trials · 50% recruiting
- 3 Waves Wellness · 2 trials · 0% recruiting
- 3EO Health · 2 trials · 0% recruiting
Sponsors near 100% open enrollment (± trial volume)
- AAVantgarde Bio Srl · 100% recruiting · 2 trials
- Acorn Biolabs · 100% recruiting · 3 trials
- Acrivon Therapeutics · 100% recruiting · 2 trials
- ADARx Pharmaceuticals · 100% recruiting · 4 trials
Related
What to do with this Sequence LifeScience page
2 registered trials is a research-attention snapshot, not an endorsement of Sequence LifeScience or any single study.
- 2 of Sequence LifeScience's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Ulcer Foot is the condition Sequence LifeScience studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Ulcer Foot trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Sequence LifeScience pipeline card: 2 registered trials from official public datasets.Report a data error.